Market Cap 130.09M
Revenue (ttm) 134.86M
Net Income (ttm) 2.35M
EPS (ttm) N/A
PE Ratio 44.00
Forward PE 103.17
Profit Margin 1.74%
Debt to Equity Ratio 0.52
Volume 220,300
Avg Vol 153,642
Day's Range N/A - N/A
Shares Out 21.02M
Stochastic %K 70%
Beta 1.81
Analysts Strong Sell
Price Target $13.62

Company Profile

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates in two segments, Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 248 291 1210
Fax: 800 455 4338
Address:
3851 West Hamlin Road, Rochester Hills, United States
StudBull
StudBull Jun. 17 at 11:10 PM
$INFU This stock is trading at 1.1X EV/Rev and 5.9X EV/EBITDA which seems way too cheap for a company expected to grow 8-10%+ this year with 18 - 20%+ EBITDA margins
0 · Reply
Bigeyes2
Bigeyes2 Jun. 14 at 6:00 PM
$INFU an inverted head and shoulders
0 · Reply
StudBull
StudBull May. 29 at 1:03 PM
$INFU Company will present at Sidoti Small-Cap Virtual Investor Conference on June 11th and 12th New Form 4 filings show two Directors buying stock in open market purchases, following buys by new CEO and CFO
0 · Reply
StudBull
StudBull May. 27 at 4:57 PM
$INFU stock is trading at 6.8X trailing EV/EBITDA, and 5.14X forward EV/EBITDA. The company is expected to continue growing +8 - 10%, with continued margin expansion. Management confirmed on the recent Q1 earnings call (double beat) that they have little (if any) tariff exposure, and little (if any) exposure to government spending cuts. The company has also been buying back stock, with management recently buying stock as well. The sell off in this stock seems full retard
1 · Reply
StudBull
StudBull May. 19 at 1:48 PM
$INFU New Form 4 filing. CEO buying stock
0 · Reply
StudBull
StudBull May. 15 at 1:48 PM
$INFU New Form 4 filing. Nice to see the CFO buying stock
0 · Reply
StudBull
StudBull May. 13 at 12:39 PM
$INFU New presentation slides: https://d1io3yog0oux5.cloudfront.net/_1fd52e9df9adf8d776aa62d8d1f9b71e/infu/db/164/2912/pdf/Exhibit+99.1+1Q25Investor+Presentation.pdf
0 · Reply
StudBull
StudBull May. 8 at 6:43 PM
$INFU Q1 2025 results crushed street estimates
0 · Reply
StockBraker
StockBraker May. 8 at 11:44 AM
1 · Reply
StudBull
StudBull Apr. 3 at 4:01 PM
$INFU I think CEO is departure is a major upgrade, and overdue
1 · Reply
Latest News on INFU
InfuSystem Reports First Quarter 2025 Financial Results

May 8, 2025, 6:30 AM EDT - 6 weeks ago

InfuSystem Reports First Quarter 2025 Financial Results


InfuSystem Set For Strong Year

Feb 10, 2025, 9:21 AM EST - 4 months ago

InfuSystem Set For Strong Year


InfuSystem Appoints Ronald Hundzinski to the Board of Directors

Nov 18, 2024, 9:15 AM EST - 7 months ago

InfuSystem Appoints Ronald Hundzinski to the Board of Directors


InfuSystem Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 6:30 AM EST - 8 months ago

InfuSystem Reports Third Quarter 2024 Financial Results


InfuSystem Set For Strong Second Half

Aug 26, 2024, 9:03 AM EDT - 10 months ago

InfuSystem Set For Strong Second Half


InfuSystem Holdings, Inc. (INFU) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 9:47 AM EDT - 11 months ago

InfuSystem Holdings, Inc. (INFU) Q2 2024 Earnings Call Transcript


InfuSystem Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 6:30 AM EDT - 11 months ago

InfuSystem Reports Second Quarter 2024 Financial Results


InfuSystem Announces $20 Million Stock Repurchase Program

May 20, 2024, 4:30 PM EDT - 1 year ago

InfuSystem Announces $20 Million Stock Repurchase Program


InfuSystem Reports First Quarter 2024 Financial Results

May 9, 2024, 6:30 AM EDT - 1 year ago

InfuSystem Reports First Quarter 2024 Financial Results


InfuSystem Holdings: 2024 Will Be A Year Of Monetization

Feb 28, 2024, 11:48 PM EST - 1 year ago

InfuSystem Holdings: 2024 Will Be A Year Of Monetization


InfuSystem Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 6:30 AM EST - 1 year ago

InfuSystem Reports Third Quarter 2023 Financial Results


InfuSystem Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 6:30 AM EDT - 2 years ago

InfuSystem Reports Second Quarter 2023 Financial Results


InfuSystem Set to Join Russell 3000® Index

Jun 21, 2023, 6:30 AM EDT - 2 years ago

InfuSystem Set to Join Russell 3000® Index


InfuSystem Reports First Quarter 2023 Financial Results

May 4, 2023, 6:30 AM EDT - 2 years ago

InfuSystem Reports First Quarter 2023 Financial Results


InfuSystem: Disappointing 2022 Results Lead To Bargain Prices

Apr 10, 2023, 10:23 AM EDT - 2 years ago

InfuSystem: Disappointing 2022 Results Lead To Bargain Prices


StudBull
StudBull Jun. 17 at 11:10 PM
$INFU This stock is trading at 1.1X EV/Rev and 5.9X EV/EBITDA which seems way too cheap for a company expected to grow 8-10%+ this year with 18 - 20%+ EBITDA margins
0 · Reply
Bigeyes2
Bigeyes2 Jun. 14 at 6:00 PM
$INFU an inverted head and shoulders
0 · Reply
StudBull
StudBull May. 29 at 1:03 PM
$INFU Company will present at Sidoti Small-Cap Virtual Investor Conference on June 11th and 12th New Form 4 filings show two Directors buying stock in open market purchases, following buys by new CEO and CFO
0 · Reply
StudBull
StudBull May. 27 at 4:57 PM
$INFU stock is trading at 6.8X trailing EV/EBITDA, and 5.14X forward EV/EBITDA. The company is expected to continue growing +8 - 10%, with continued margin expansion. Management confirmed on the recent Q1 earnings call (double beat) that they have little (if any) tariff exposure, and little (if any) exposure to government spending cuts. The company has also been buying back stock, with management recently buying stock as well. The sell off in this stock seems full retard
1 · Reply
StudBull
StudBull May. 19 at 1:48 PM
$INFU New Form 4 filing. CEO buying stock
0 · Reply
StudBull
StudBull May. 15 at 1:48 PM
$INFU New Form 4 filing. Nice to see the CFO buying stock
0 · Reply
StudBull
StudBull May. 13 at 12:39 PM
$INFU New presentation slides: https://d1io3yog0oux5.cloudfront.net/_1fd52e9df9adf8d776aa62d8d1f9b71e/infu/db/164/2912/pdf/Exhibit+99.1+1Q25Investor+Presentation.pdf
0 · Reply
StudBull
StudBull May. 8 at 6:43 PM
$INFU Q1 2025 results crushed street estimates
0 · Reply
StockBraker
StockBraker May. 8 at 11:44 AM
1 · Reply
StudBull
StudBull Apr. 3 at 4:01 PM
$INFU I think CEO is departure is a major upgrade, and overdue
1 · Reply
StudBull
StudBull Apr. 1 at 2:22 PM
$INFU Expected 8-10% growth and continued margin expansion, with multiple growth options and demographic tailwinds. What am I missing?
0 · Reply
DonCorleone77
DonCorleone77 Apr. 1 at 10:42 AM
$INFU InfuSystem still sees 2025 revenue growth 8%-10% from $134.86M in 2024 Consensus for 2025 revenue is $146.48M. Sees 2025 adjusted EBITDA margin in the high teens, exceeding the company's margin of 18.8% in 2024.
0 · Reply
StudBull
StudBull Mar. 28 at 9:51 PM
$INFU the current stock price is extremely frustrating. I’m hoping it motivates the board to light a fire under management, esp the CEO who can come across in investor calls as needing a much greater sense of urgency
1 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 21 at 11:17 PM
$INFU Digging INFU's strategic moves in oncology and wound care. Solid fundamentals with consistent revenue growth. Device Solutions segment looking promising. Might add to my portfolio on next dip. Watching closely for Q1 performance and tech upgrade impact. valuable article: https://beyondspx.com/article/infusystem-holdings-inc-infu-a-versatile-healthcare-provider-powering-patient-outcomes
0 · Reply
StudBull
StudBull Mar. 20 at 6:04 PM
$INFU https://x.com/CMPdevice/status/1902374150880296995
0 · Reply
StudBull
StudBull Mar. 12 at 5:10 PM
$INFU Chemo Mouthpiece website has been upgraded https://chemomouthpiece.com/
0 · Reply
d_risk
d_risk Mar. 11 at 9:49 PM
$INFU - InfuSystems Holdings Inc. Common Stock - 10K - Updated Risk Factors INFU's 2025 10-K Risk Factors highlight increased reliance on a single supplier, expanded focus on U.S. healthcare reforms, geopolitical instability, and cybersecurity risks, alongside new risks from tech upgrades and privacy concerns. #Risk https://d-risk.ai/INFU/10-K/2025-03-11
1 · Reply
StudBull
StudBull Mar. 7 at 5:46 PM
$INFU earnings summary https://www.stocktitan.net/news/INFU/infu-system-announces-operational-and-financial-results-for-fourth-jh3o4dz2fi9i.html
0 · Reply
StudBull
StudBull Mar. 6 at 8:20 PM
$INFU Seems like compelling value for a healthcare company expecting +8-10% growth and 18.8%+ EBITDA margins
1 · Reply
StudBull
StudBull Mar. 4 at 2:03 PM
2 · Reply
StudBull
StudBull Mar. 4 at 12:29 PM
$INFU “Company executed stock repurchases totaling $1.2 million during fiscal 2024 and in the first quarter of 2025, we executed a block purchase of approximately $2.4 million,”
0 · Reply
DonCorleone77
DonCorleone77 Mar. 4 at 12:08 PM
$INFU InfuSystem sees FY25 revenue growth 8%-10%, consensus $147.89M "InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting adjusted EBITDA margin to be in the high-teens, exceeding the company's margin of 18.8% in 2024, this despite the planned continued investment in the company's information technology systems. The company intends to update its annual guidance throughout the year."
0 · Reply